Durable MRD-negative remission with blinatumomab and venetoclax in heavily pretreated relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Document Type
Report
Department
Medical College Pakistan
Abstract
Introduction: Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
Methods: We report the case of a heavily pretreated patient with relapsed/refractory Ph+ ALL treated with blinatumomab and venetoclax without concurrent TKI therapy.
Results: The patient achieved complete remission and remains in a deep, durable remission exceeding 1 year.
Conclusion: This case highlights a potential kinase-independent, TKI-free strategy for relapsed/refractory Ph+ ALL, warranting further investigation.
Publication (Name of Journal)
eJHaem
DOI
10.1002/jha2.70317
Recommended Citation
Qadir, M. S.,
Farooq, S.,
Jamy, O.
(2026). Durable MRD-negative remission with blinatumomab and venetoclax in heavily pretreated relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. eJHaem, 7(3), 1-4.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_mc/671